Sains Malaysiana 46(2)(2017): 217–221

http://dx.doi.org/10.17576/jsm-2017-4602-05

Efficacy Evaluation of Combination Vaccine of Recombinant C-Terminal Fragments of ApxIA, ApxIIA and ApxIIIA in Piglets

(Penilaian Kemujaraban Gabungan Vaksin Rekombinan Terminal-C Serpihan ApxIA, ApxIIA dan ApxIIIA pada Anak Babi)

JA YONG MOON¹, JI YOUNG KANG², JEONG-WOO SEO², WON KYONG KIM¹, YEONG HWAN CHOI¹, MIN SOO CHOI¹ & JIN HUR¹*

¹Department of Bioactive Material Sciences and Department of Veterinary Public Health, College of Veterinary Medicine, Chonbuk National University Iksan Campus Iksan 54596, South Korea

²Industrial Microbiology and Bioprocess Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Jeongeup-si, 580-185, Republic of Korea

Received: 25 January 2016/Accepted: 7 June 2016

ABSTRACT

The efficacy of the combination vaccine of the individual C-terminal fragments of ApxIA, ApxIIA and ApxIIIA of Actinobacillus pleuropneumoniae (APP) was evaluated in piglets. Twenty piglets were divided equally into 2 groups (n=10). All piglets were intramuscularly primed at 4 week-of-age (0 week post prime inoculation (WPPI)) and were intramuscularly boosted at 6 week-of-age (2 WPPI). Group A piglets were inoculated with sterile PBS and group B piglets were inoculated with the combination vaccine. Concentrations of each of the C-terminal fragment-specific IgG as determined by ELISA were significantly higher in group B than in group A from 2 WPPI until the end of this study. Clinical signs were observed from only 10% of group B piglets after the challenge with the mixture of APP serotypes 1, 2 and 5 at 4 WPPI, while 50% of group A piglets were protected against APP infections. Overall, intramuscular inoculation with the vaccine candidate can efficiently protect piglets against APP infection.

Keywords: Actinobacillus pleuropneumoniae; immunization; piglets; porcine pleuropneumonia; protection

ABSTRAK

Keberkesanan kombinasi vaksin oleh serpihan terminal-C individu ApxIA, ApxIIA dan ApxIIIA daripada Actinobacillus pleuropneumoniae (APP) dinilai pada anak babi. Dua puluh anak babi dibahagikan sama rata kepada 2 kumpulan (n=10). Semua anak babi telah mencapai intraotot primer pada umur 4 minggu (0 minggu selepas inokulasi utama (WPPI)) dan telah dirangsang intraototnya pada umur 6 minggu (2 WPPI). Anak babi kumpulan A telah diinokulasi dengan PBS steril dan anak babi kumpulan B telah diinokulasi dengan vaksin kombinasi. Kepekatan setiap IgG fragmen-tertentu terminal-C seperti yang ditetapkan oleh ELISA adalah jauh lebih tinggi dalam kumpulan B daripada kumpulan A daripada 2 WPPI sehingga ke penghujung kajian ini. Tanda klinikal diperhatikan pada 10% daripada anak babi kumpulan B selepas cabaran dengan campuran serotip APP 1, 2 dan 5 pada 4 WPPI, manakala 50% anak babi kumpulan A dilindungi daripada jangkitan APP. Secara keseluruhannya, inokulasi intraotot dengan calon vaksin boleh melindungi anak babi terhadap jangkitan APP dengan cekap.

Kata kunci: Actinobacillus pleuropneumoniae; anak babi; imunisasi; perlindungan; porcine pleuropneumonia

REFERENCES

Blackall, P.J., Klaasen, H.L., van den Bosch, H., Kuhnert, P. & Frey, J. 2002. Proposal of a new serovar of Actinobacillus pleuropneumoniae: Serovar 15. Vet. Microbiol. 84: 47-52.

Chen, X., Xu, Z., Li, L., Chen, H. & Zhou, R. 2012. Identification of conserved surface proteins as novel antigenic vaccine candidates of Actinobacillus pleuropneumoniae. J. Microbiol 50: 978-986.

Cruijsen, T., Van Leengoed, L., Dekker-Nooren, T.C., Schoevers, J.H. & Verheijden, J.H. 1992. Phagocytosis and killing of Actinobacillus pleuropneumoniae by alveolar macrophages and polymorphonuclear leukocytes isolated from pigs. Infect. Immun. 60: 4867-4871.

Fenwick, B. & Henry, S. 1994. Porcine pleuropneumoniae. J. Am. Vet. Med. Assoc. 204: 1334-1340.

Frey, J. & Kuhnert, P. RTX toxins in Pasteurellaceae. Int. J. Med. Microbiol. 292: 149-158.

Haesebrouck, F., Pasmans, F., Chiers, K., Maes, D., Ducatelle, R. & Decostere, A. 2004. Efficacy of vaccines against bacterial diseases in swine: What can we expect? Vet. Microbiol. 100: 255-268.

Holmgren, J. & Czerkinsky, C. 2005. Mucosal immunity and vaccines. Nat. Med. 11: S45-S53.

Hur, J. & Lee, J.H. 2014. Optimization of immune strategy for a construct of Salmonella-delivered ApxIA, ApxIIA, ApxIIIA and OmpA antigens of Actinobacillus pleuropneumoniae for prevention of porcine pleuropneumonia using a murine model. Vet. Res. Commum 38: 87-91.

Jessing, S.G., Angen, Ø. & Inzana, T.J. 2003. Evaluation of a multiplex PCR test for simultaneous identification and serotyping of Actinobacillus pleuropneumoniae. J. Clin. Microbiol. 41: 4095-4100.

Jessing, S.G., Ahrens, P., Inzana, T.J. & Angen, Ø. 2008. The genetic organisation isolation of the capsule biosynthesis region of Actinobacillus pleuropneumoniae serotypes 1, 6, 7 and 12. Vet. Microbiol. 129: 350-359.

Kamp, E.M., Stockhofe-Zurwieden, N., van Leengoed, L.A & Smits, M.A. 1997. Endobronchial inoculation with Apx toxins of Actinobacillus pleuropneumoniae leadsto pleuropneumonia in pigs. Infect. Immun. 65: 4350-4354.

Kim, B., Min, K., Choi, C., Cho, W.S., Cheon, D.S., Kwon, D., Kim, J. & Chae, C. 2001. Antimicrobial susceptibility of Actinobacillus pleuropneumoniae isolated from pigs in Korea using new standardized procedures. J. Vet. Med. Sci 63: 341-342.

Lee, K.E., Choi, H.W., Kim, H.H., Song, J.Y. & Yang, D.K. 2015. Prevalence and characterization of Actinobacillus pleuropneumoniae isolated from Korean pigs. J. Bacteriol. Virol. 45: 19-25.

Liao, C.W., Chiou, H.Y., Yeh, K.S., Chen, J.R. & Weng, C.N. 2003. Oral immunization using formalin-inactivated Actinobacillus pleuropneumoniae antigens entrapped in microspheres with aqueous dispersion polymers prepared using a co-spray drying process. Prev. Vet. Med. 61: 1-15.

Lu, Y.C., Li, M.C., Chen, Y.M., Chu, C.Y., Lin, S.F. & Yang, W.J. 2011. DNA vaccine encoding type IV pilin of Actinobacillus pleuropneumoniae induces strong immune response but confers limited protective efficacy against serotype 2 challenge. Vaccine 29: 7740-7746.

MacDonald, T.T. 2003. The mucosal immune system. Parasite. Immunol. 25: 235-246.

Ramjeet, M., Deslandes, V., Goure, J. & Jacques, M. 2008. Actinobacillus pleuropneumoniae vaccines: from bacterins to new insights into vaccination strategies. Anim. Health. Res. Rev 9: 25-45.

Rycroft, A.N., Williams, D., Cullen, J.M. & Macdonald, J. 1991. The cytotoxin of Actinobacillus pleuropneumoniae (pleurotoxin) is distinct from the haemolysin and is associated with a 120 kDa polypeptide. J. Gen. Microbiol. 137: 561-568.

Shin, S.J., Bae, J.L., Cho, Y.W., Lee, D.Y., Kim, D.H., Yang, M.S., Jang, Y.S. & Yoo, H.S. 2005. Induction of antigen-specific immune responses by oral vaccination with Saccharomyces cerevisiae expressing Actinobacillus pleuropneumoniae ApxIIA. FEMS. Immunol. Med. Microbiol. 43: 155-164.

Tumamao, J.Q., Bowles, R.E., van den Bosch, H., Klaasen, H.L., Fenwick, B.W. & Blackall, P.J. 2004. An evaluation of the role of antibodies to Actinobacillus pleuropneumoniae serovar 1 and 15 in the protection provided by sub-unit and live streptomycin-dependent pleuropneumonia vaccines. Aust. Vet. J. 82: 773-780.

Yoo, A.N., Cha, S.B., Shin, M.K., Won, H.K., Kim, E.H., Choi, H.W. & Yoo, H.S. 2014. Serotype and antimicrobial resistance patterns of the recent Korean Actinobacillus pleuropneumoniae isolates. Vet. Rec 174: 223.

Zhou, Y., Li, L., Chen, Z., Yuan, H., Chen, H. & Zhou, R. 2013. Adhesion protein ApfA of Actinobacillus pleuropneumoniae is required for pathogenesis and is a potential target for vaccine development. Clin. Vaccine. Immunol. 20: 287-294.

*Corresponding author; email: hurjin@jbnu.ac.kr